Type 2 diabetes
Conditions
Interventions
Switching from liraglutide (0.9-1.8mg/day) to once-weekly semaglutide (0.25-1.0mg/week)
Continue liraglutide (0.9-1.8mg/day)
Switching from dulaglutide (0.75mg/week) to once-weekly semaglutide (0.25-
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) HbA1c 6.0-10.0% 2) BMI >= 22 kg/m2 3) patients who were treated with liraglutide or dulaglutide at least for 12 weeks 4) written informed consent
Exclusion criteria
Exclusion criteria: 1) patients with type 2 diabetes who were treated with GLP-1 receptor agonist other than liraglutide or dulaglutide 2) history of anaphylaxis of semaglutide 3) unstable retinopathy 4) severe hepatic dysfunction or renal dysfunction 5) severe ketosis, diabetic coma 6) severe infection, surgery, serious trauma 7) pregnancy 8) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in HbA1c from baseline at 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The change in QOL scores 2) Adverse effects 3) The change in weight, abdominal circumference, blood pressure and pulse 4) The change in the other blood and urinary tests 5) The factors associated with improvement of HbA1c and secondary endpoints 6) Comparison of the changes between plan A and B when semaglutide demonstrates the superiority compared to both conventional GLP-1 receptor agonists | — |
Countries
Japan
Contacts
Public ContactAkinobu Nakamura
Hokkaido University Hospital Diabetes and Endocrinology
Outcome results
None listed